Table 2

Total number of patients (%) with any adverse event and decrease in platelet
Adverse events number of patients (%) Percentage decrease in platelet number of patients (%)
Part Treatment group (N) Any AE Any AE (days 1–28) 25 to 38% 39 to 51% 52 to 85% All
A 0.03/0.06 mg/kg IV (N = 4)a 2 (50) 1 (25) 0 0 0 0
0.3 mg/kg IV (N = 8)a 2 (25) 2 (25) 1 (13%) 0 0 1 (13%)
3 mg/kg IV (N = 12) 7 (58) 5 (42) 6 (50%) 0 0 6 (50%)
10 mg/kg IV (N = 12) 6 (50) 5 (42) 4 (33%) 0 1 (8%) 5 (42%)
20 mg/kg IV (N = 6) 5 (83) 4 (67) 2 (33%) 2 (33%) 0 4 (67%)
30 mg/kg IV (N = 6) 4 (67) 3 (50) 1 (17%) 2 (33%) 0 3 (50%)
B 6 mg/kg repeat IV (N = 37) 15 (41) 8 (22) 10 (27%) 4 (11%) 1 (3%) 15 (41%)
C 500 mg SC (N = 12) 6 (50) 6 (50) 5 (42%) 2 (17%) 0 7 (58%)
Pooled (Parts A, B, C) All Placebo (N = 38) 12 (32) 8 (21) 8 (21%) 1 (3%) 1 (3%) 10 (26%)

AE, adverse event; IV, intravenous patient; SC, subcutaneous patient.

Choy et al.

Choy et al. Arthritis Research & Therapy 2013 15:R132   doi:10.1186/ar4312

Open Data